Although aberrant T/NK-cell antigen expression is observed approximately 10% of B cell precursor acute lymphoblastic leukemia (BCP-ALL), the bright positivity of CD56 is exceedingly rare [1] [2] [3] . Here, we describe the first reported case, at least to our knowledge, of KMT2A-AFF1-rearranged BCP-ALL that co-expressed CD34, CD19, cytoplasmic (cyt) CD79a, and CD56 without any other lineage markers developed in a pregnant woman and successfully treated by allogeneic hematopoietic cell transplantation.
showed a 47, XX, +X, t(4;11)(q21;11q23.3) karyotype suggesting a diagnosis of KMT2A-rearranged BCP-ALL, which was confirmed by the molecular detection of KMT2A-AFF1 fusion transcript. After delivery of a female newborn by Cesarean section at 32 weeks pregnant, she had started to receive intensive chemotherapy by use of the hyper-CVAD regimen [2] , which led her disease to sustained molecular remission. The delivered infant did not show any hematologic abnormalities that denied the possibility of fetal cell-derived maternal leukemia. Considering the high-risk nature of KMT2A-AFF1-rearranged BCP-ALL with hyperleukocytosis, we decided to perform allogeneic peripheral blood stem-cell transplantation from her HLA identical sister using myeloablative conditioning consisting of fludarabine 120 mg/m 2 , intravenous busulfan 12.8 mg/kg, and melphalan 140 mg/m 2 as a consolidative treatment. She has maintained molecular remission with good performance status with mild skin chronic GVHD more than 2 years after transplantation.
Aberrant expression of CD56 is commonly observed in acute myeloid leukemia, whereas its expression in lymphoblastic leukemia is a relatively rare event. BCP-ALL with KMT2A-AFF1 is a common subtype of KMT2A-rearranged leukemia characterized by frequent occurrence in infants with dismal clinical course [4] . In a more recent study, KMT2A-AFF1 was also shown to be the most prevalent translocation in adult patients with Philadelphia chromosome-negative BCP-ALL and associated with a worse outcome independent of age [5] . Although its etiology and cellular origin remain an enigma, KMT2A-AFF1 fusion gene was shown to be present in primitive CD34+CD19− lymphoid progenitors [6] . Because those common lymphoid progenitors usually differentiate into innate lymphoid cells via expression of CD56 [7] , aberrant CD56 expression in our patient might suggest the bidirectional differentiation potential of very early B cell progenitors characterized by CD34+CD10−CD19+ phenotype, a putative origin of KMT2A-AFF1-rearranged BCP-ALL. It is also important to note here that CD34+CD10−CD19+ B cell precursors might arise from distinct developmental pathways from CD34+CD10+CD19+ pro-B cells [8] . Because the promoter of CD56 gene contains sequences that allow binding of various transcription factors such as RUNX1, BTB3, Pax5, MMSET, and Cyclin D1 [9] , more simple explanation of aberrant CD56 expression in this particular case might be dysregulated transcriptome of leukemic cells. Finally, although the prognostic impact of CD56 expression in KMT2A-AFF1-rearranged BCP-ALL has yet to be elucidated, our present experience suggests that sustained remission can be achieved by allogeneic hematopoietic cell transplantation performed at an appropriate timing.
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